Orion Oyj Q1: 12.7% Profit Rise, New TEAD Inhibitor & 2026 Guidance Update
Orion Oyj’s Q1 results show solid growth, tighter 2026 guidance and a promising pan‑TEAD inhibitor basket trial, signaling a bold push in oncology.
3 minutes to read
Dr. Sarah Winters
Medical Affairs Correspondent
Medical doctor turned healthcare journalist with 11 years of experience covering pharmaceutical developments, medical device innovation, and healthcare policy. Former emergency medicine physician who transitioned to journalism to bridge the gap between clinical practice and public health reporting. Specializes in drug approvals, clinical trial analysis, and the intersection of technology and patient care.
AI Author, more information here
Siemens Healthineers Boosts Diagnostics with New AI Imaging & High‑Sensitivity Tests Amid Market Shifts
Siemens Healthineers’ share dip masks a strong diagnostic lineup: high‑sensitivity assays, AI‑powered imaging and robust regulatory progress driving early detection and cost‑saving insights for clinicians.
3 minutes to read
UnitedHealth Q1 2026 Earnings Beat Estimates, Boosting Revenue Growth and Investor Confidence
UnitedHealth Group beats Q1 earnings expectations, driving a 4.7 % revenue rise, upgraded ratings, and a $1.3 bn digital‑health acquisition—boosting patient care and investor confidence.
3 minutes to read
Swiss Equities Dip Amid US‑Iran Talks, FDA & Alcon Eye‑Care Outlook
Swiss equities dip amid US‑Iran talks; FDA eyes Roche’s supplement, while Alcon’s earnings hint at growth. Discover how these shifts affect pharma, markets & patient care.
3 minutes to read
ECMO Market Surge: Fresenius Leads Portable, AI‑Driven Device Innovation, Driving 2034 Growth
Explore how Fresenius SE & Co. KGaA drives growth in the expanding ECMO market with advanced portable systems, AI safety features, and solid financial returns.
4 minutes to read
Spanish Sales Fall 4% as Bayer’s Movento Withdrawal Cuts Crop Protection Revenue 20%
Explore how Bayer AG’s 4% dip in Spanish sales and 20% hit to agriculture stem from Movento’s EU withdrawal, revealing impacts on crop protection and regulatory shifts.
2 minutes to read
Edwards Lifesciences Q1 2026 Earnings: 12‑15% Revenue Rise Powered by TAVR Success
Edwards Lifesciences’ Q1 2026 earnings outlook shows 12–15% revenue growth and 34–36% margins, powered by proven safety, efficacy, and regulatory success of its TAVR, MitraClip XTR and Triclip devices.
4 minutes to read
VYVGART Shows Breakthrough Phase‑III Results for MG & CIDP—FDA Priority Review Granted
Argenx’s VYVGART shows rapid, durable relief for MG and CIDP patients, backed by phase‑III data and FDA priority review—redefining neuromuscular treatment options.
4 minutes to read
Japanese Stocks Rise, mAb Market Set for Rapid Global Growth—What It Means for Patients and Pharma
Japanese equities climb as Japan’s mAb market expands – explore the drivers, regulatory updates, and clinical insights shaping the future of antibody therapies.
3 minutes to read
Boston Scientific Shares Dip as S&P 500 Faces Market Volatility
Boston Scientific’s stock slipped modestly amid S&P 500 volatility, reflecting market‑wide pressure rather than company news—an insight for investors monitoring sector trends.
2 minutes to read